Top

Journal of Autism and Developmental Disorders

Gepubliceerd in:

01-11-2010 | Brief Report

Brief Report: Acamprosate in Fragile X Syndrome

Auteurs: Craig A. Erickson, Jennifer E. Mullett, Christopher J. McDougle

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 11/2010

Abstract

Glutamatergic dysfunction is implicated in the pathophysiology of fragile X syndrome (FXS). We report on the first trial of acamprosate, a drug with putative mGluR5 antagonism, in three adults with FXS and autism. Medical records describing open-label treatment with acamprosate in 3 patients with FXS and a comorbid diagnosis of autistic disorder were reviewed. In all three patients, acamprosate was associated with improved linguistic communication. Three patients received acamprosate over a mean 21.3 weeks of treatment. All patients showed global clinical benefit as rated with the Clinical Global Impressions-Improvement scale. Marked communication improvement was unexpected and has potential implications for the treatment of FXS, as well as idiopathic autism.

vorige artikel A Comparison of the Development of Audiovisual Integration in Children with Autism Spectrum Disorders and Typically Developing Children

volgende artikel Ron Leaf, John McEachin (eds): A Work in Progress: Behavior Management Strategies and a Curriculum for Intensive Behavioral Treatment of Autism

al Qatari, M., Khan, S., Harris, B., & Littleton, J. (2001). Acamprosate is neuroprotective against glutamate-induced excitotoxicity when enhanced by ethanol withdrawal in neocortical cultures of fetal rat brain. Alcoholism, Clinical and Experimental Research, 25(9), 1276–1283.CrossRefPubMed

American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders, Four Edition, Text Revision (4th ed.). Washington, DC: American Psychiatric Association.CrossRef

Bear, M. F., Huber, K. M., & Warren, S. T. (2004). The mGluR theory of fragile X mental retardation. Trends in Neurosciences, 27(7), 370–377.CrossRefPubMed

Berry-Kravis, E., Hessl, D., Coffey, S., Hervey, C., Schneider, A., Yuhas, J., et al. (2009). A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. Journal of Medical Genetics, 46(4), 266–271.CrossRefPubMed

Berry-Kravis, E., Sumis, A., Hervey, C., Nelson, M., Porges, S. W., Weng, N., et al. (2008). Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. Journal of Developmental and Behavioral Pediatrics, 29(4), 293–302.CrossRefPubMed

Blednov, Y. A., & Adron Harris, R. (2008). Metabotropic glutamate receptor 5 (mGluR5) regulation of ethanol sedation, dependence and consumption: Relationship to acamprosate actions. International Journal of Neuropsychopharmacology, 11(6), 775–793.PubMed

Chuang, S. C., Zhao, W., Bauchwitz, R., Yan, Q., Bianchi, R., & Wong, R. K. (2005). Prolonged epileptiform discharges induced by altered group I metabotropic glutamate receptor-mediated synaptic responses in hippocampal slices of a fragile X mouse model. Journal of Neuroscience, 25(35), 8048–8055.CrossRefPubMed

de Diego-Otero, Y., Romero-Zerbo, Y., el Bekay, R., Decara, J., Sanchez, L., Rodriguez-de Fonseca, F., et al. (2009). Alpha-tocopherol protects against oxidative stress in the fragile X knockout mouse: An experimental therapeutic approach for the Fmr1 deficiency. Neuropsychopharmacology, 34(4), 1011–1026.CrossRefPubMed

de Vrij, F. M., Levenga, J., van der Linde, H. C., Koekkoek, S. K., De Zeeuw, C. I., Nelson, D. L., et al. (2008). Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiology of Diseases, 31(1), 127–132.CrossRef

De Witte, P., Littleton, J., Parot, P., & Koob, G. (2005). Neuroprotective and abstinence-promoting effects of acamprosate: Elucidating the mechanism of action. CNS Drugs, 19(6), 517–537.CrossRefPubMed

Devys, D., Lutz, Y., Rouyer, N., Bellocq, J. P., & Mandel, J. L. (1993). The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation. Nature Genetics, 4(4), 335–340.CrossRefPubMed

Dolen, G., & Bear, M. F. (2008). Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome. Journal of Physiology, 586(6), 1503–1508.CrossRefPubMed

Dolen, G., Osterweil, E., Rao, B. S., Smith, G. B., Auerbach, B. D., Chattarji, S., et al. (2007). Correction of fragile X syndrome in mice. Neuron, 56(6), 955–962.CrossRefPubMed

el Bekay, R., Romero-Zerbo, Y., Decara, J., Sanchez-Salido, L., Del Arco-Herrera, I., Rodriguez-de Fonseca, F., et al. (2007). Enhanced markers of oxidative stress, altered antioxidants and NADPH-oxidase activation in brains from Fragile X mental retardation 1-deficient mice, a pathological model for Fragile X syndrome. European Journal of Neuroscience, 26(11), 3169–3180.CrossRefPubMed

Erickson, C. A., Mullett, J. E., & McDougle, C. J. (2009). Open-label memantine in Fragile X Syndrome. J Autism Dev Disord.

Forest Pharmaceuticals Inc. (2005). Campral Product Information Retrieved August 17, 2009, from http://www.frx.com/pi/campral_pi.pdf.

Greenough, W. T., Klintsova, A. Y., Irwin, S. A., Galvez, R., Bates, K. E., & Weiler, I. J. (2001). Synaptic regulation of protein synthesis and the fragile X protein. Proc Natl Acad Sci USA, 98(13), 7101–7106.CrossRefPubMed

Gupta, T., Syed, Y. M., Revis, A. A., Miller, S. A., Martinez, M., Cohn, K. A., et al. (2008). Acute effects of acamprosate and MPEP on ethanol Drinking-in-the-Dark in male C57BL/6J mice. Alcoholism, Clinical and Experimental Research, 32(11), 1992–1998.PubMed

Guy, W. (1976). ECDEU assessment manual for psychopharmacology, Publication No. 76–338. Washington, DC: US DHEW, NIMH.

Hagerman, P. J. (2008). The fragile X prevalence paradox. Journal of Medical Genetics, 45(8), 498–499.CrossRefPubMed

Harris, B. R., Prendergast, M. A., Gibson, D. A., Rogers, D. T., Blanchard, J. A., Holley, R. C., et al. (2002). Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcoholism, Clinical and Experimental Research, 26(12), 1779–1793.PubMed

Jaeschke, G., Wettstein, J. G., Nordquist, R. E., & Spooren, W. (2008). mGlu5 receptor antagonists and their potential therapeutic potential. Expert Opinion on Therapeutic Patents, 18(2), 123–142.CrossRef

Lord, C., Rutter, M., & Le Couteur, A. (1994). Autism diagnostic interview-revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. Journal of Autism and Developmental Disorders, 24(5), 659–685.CrossRefPubMed

Mann, K., Kiefer, F., Spanagel, R., & Littleton, J. (2008). Acamprosate: Recent findings and future research directions. Alcoholism, Clinical and Experimental Research, 32(7), 1105–1110.CrossRefPubMed

McBride, S. M., Choi, C. H., Wang, Y., Liebelt, D., Braunstein, E., Ferreiro, D., et al. (2005). Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron, 45(5), 753–764.CrossRefPubMed

Pieretti, M., Zhang, F. P., Fu, Y. H., Warren, S. T., Oostra, B. A., Caskey, C. T., et al. (1991). Absence of expression of the FMR-1 gene in fragile X syndrome. Cell, 66(4), 817–822.CrossRefPubMed

Reilly, M. T., Lobo, I. A., McCracken, L. M., Borghese, C. M., Gong, D., Horishita, T., et al. (2008). Effects of acamprosate on neuronal receptors and ion channels expressed in Xenopus oocytes. Alcoholism, Clinical and Experimental Research, 32(2), 188–196.CrossRefPubMed

Romero-Zerbo, Y., Decara, J., el Bekay, R., Sanchez-Salido, L., Del Arco-Herrera, I., de Fonseca, F. R., et al. (2009). Protective effects of melatonin against oxidative stress in Fmr1 knockout mice: A therapeutic research model for the fragile X syndrome. Journal of Pineal Research, 46(2), 224–234.CrossRefPubMed

Ronesi, J. A., & Huber, K. M. (2008). Metabotropic glutamate receptors and fragile x mental retardation protein: Partners in translational regulation at the synapse. Sci Signal, 1(5), pe6.

Yan, Q. J., Rammal, M., Tranfaglia, M., & Bauchwitz, R. P. (2005). Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology, 49(7), 1053–1066.CrossRefPubMed

Titel: Brief Report: Acamprosate in Fragile X Syndrome
Auteurs: Craig A. Erickson
Jennifer E. Mullett
Christopher J. McDougle
Publicatiedatum: 01-11-2010
Uitgeverij: Springer US
Gepubliceerd in: Journal of Autism and Developmental Disorders / Uitgave 11/2010
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI: https://doi.org/10.1007/s10803-010-0988-9

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen

Andere artikelen Uitgave 11/2010

Decontextualised Minds: Adolescents with Autism are Less Susceptible to the Conjunction Fallacy than Typically Developing Adolescents

Stimulus Overselectivity Four Decades Later: A Review of the Literature and Its Implications for Current Research in Autism Spectrum Disorder

A Comparison of the Development of Audiovisual Integration in Children with Autism Spectrum Disorders and Typically Developing Children

Explaining and Selecting Treatments for Autism: Parental Explanatory Models in Taiwan

RCT of a Manualized Social Treatment for High-Functioning Autism Spectrum Disorders

The Heavy Burden of Psychiatric Comorbidity in Youth with Autism Spectrum Disorders: A Large Comparative Study of a Psychiatrically Referred Population